JP2023527153A - 非アルコール性脂肪性肝炎（ｎａｓｈ）の処置 - Google Patents

非アルコール性脂肪性肝炎（ｎａｓｈ）の処置 Download PDF

Info

Publication number
JP2023527153A
JP2023527153A JP2022570474A JP2022570474A JP2023527153A JP 2023527153 A JP2023527153 A JP 2023527153A JP 2022570474 A JP2022570474 A JP 2022570474A JP 2022570474 A JP2022570474 A JP 2022570474A JP 2023527153 A JP2023527153 A JP 2023527153A
Authority
JP
Japan
Prior art keywords
25hc3s
salt
subject
day
nash
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022570474A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527153A5 (https=
JPWO2021237143A5 (https=
Inventor
リン，ウェイチー
Original Assignee
デュレクト コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デュレクト コーポレーション filed Critical デュレクト コーポレーション
Publication of JP2023527153A publication Critical patent/JP2023527153A/ja
Publication of JP2023527153A5 publication Critical patent/JP2023527153A5/ja
Publication of JPWO2021237143A5 publication Critical patent/JPWO2021237143A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2022570474A 2020-05-22 2021-05-21 非アルコール性脂肪性肝炎（ｎａｓｈ）の処置 Pending JP2023527153A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063029361P 2020-05-22 2020-05-22
US63/029,361 2020-05-22
US202063030207P 2020-05-26 2020-05-26
US63/030,207 2020-05-26
US202063113116P 2020-11-12 2020-11-12
US63/113,116 2020-11-12
US202163146555P 2021-02-05 2021-02-05
US63/146,555 2021-02-05
PCT/US2021/033743 WO2021237143A1 (en) 2020-05-22 2021-05-21 Treatment of non-alcoholic steatohepatitis (nash)

Publications (3)

Publication Number Publication Date
JP2023527153A true JP2023527153A (ja) 2023-06-27
JP2023527153A5 JP2023527153A5 (https=) 2024-05-28
JPWO2021237143A5 JPWO2021237143A5 (https=) 2024-05-28

Family

ID=78707644

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022570474A Pending JP2023527153A (ja) 2020-05-22 2021-05-21 非アルコール性脂肪性肝炎（ｎａｓｈ）の処置

Country Status (11)

Country Link
US (1) US20230181601A1 (https=)
EP (1) EP4153164A4 (https=)
JP (1) JP2023527153A (https=)
KR (1) KR20230015939A (https=)
CN (1) CN115916181A (https=)
AU (1) AU2021273936A1 (https=)
BR (1) BR112022022737A2 (https=)
CA (1) CA3195103A1 (https=)
MX (1) MX2022014575A (https=)
TW (1) TW202210081A (https=)
WO (1) WO2021237143A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3494125B1 (en) 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016510720A (ja) * 2013-03-15 2016-04-11 持田製薬株式会社 非アルコール性脂肪性肝炎治療のための組成物および方法
WO2018193006A1 (en) * 2017-04-18 2018-10-25 Genfit Combination of elafibranor or derivatives thereof with an anti-nash, anti-fibrotic or anti-cholestatic agent
WO2019071216A1 (en) * 2017-10-06 2019-04-11 Gilead Sciences, Inc. POLYTHERAPY COMPRISING AN ACC INHIBITOR
JP2019526542A (ja) * 2016-08-02 2019-09-19 デュレクト コーポレーション 酸素化コレステロールサルフェート、並びにポリアルキレングリコール、カルボキシメチルセルロース、及びポリオキシルグリセリドのうち少なくとも１種を含む組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
US8399441B2 (en) * 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US9034859B2 (en) * 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
ES2869884T3 (es) * 2011-09-16 2021-10-26 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y la enfermedad de hígado graso no alcohólico
EP3494125B1 (en) * 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016510720A (ja) * 2013-03-15 2016-04-11 持田製薬株式会社 非アルコール性脂肪性肝炎治療のための組成物および方法
JP2019526542A (ja) * 2016-08-02 2019-09-19 デュレクト コーポレーション 酸素化コレステロールサルフェート、並びにポリアルキレングリコール、カルボキシメチルセルロース、及びポリオキシルグリセリドのうち少なくとも１種を含む組成物
WO2018193006A1 (en) * 2017-04-18 2018-10-25 Genfit Combination of elafibranor or derivatives thereof with an anti-nash, anti-fibrotic or anti-cholestatic agent
WO2019071216A1 (en) * 2017-10-06 2019-04-11 Gilead Sciences, Inc. POLYTHERAPY COMPRISING AN ACC INHIBITOR

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
""Safety and pharmacokinetics of DUR-928 in patients with nonalcoholic steatohepatitis - A phase 1b s", JOURNAL OF HEPATOLOGY, vol. 66(1), JPN6025020840, 2017, pages 596, ISSN: 0005807171 *
GASTROENTEROLOGY & HEPATOLOGY, vol. 16(4), JPN6025020841, April 2020 (2020-04-01), pages 178 - 189, ISSN: 0005807172 *
METABOLISM, vol. 71, JPN6025020842, 2017, pages 17 - 32, ISSN: 0005807173 *

Also Published As

Publication number Publication date
KR20230015939A (ko) 2023-01-31
CA3195103A1 (en) 2021-11-25
TW202210081A (zh) 2022-03-16
MX2022014575A (es) 2022-12-15
AU2021273936A1 (en) 2022-12-08
BR112022022737A2 (pt) 2023-01-31
CN115916181A (zh) 2023-04-04
EP4153164A4 (en) 2024-06-26
US20230181601A1 (en) 2023-06-15
WO2021237143A1 (en) 2021-11-25
EP4153164A1 (en) 2023-03-29

Similar Documents

Publication Publication Date Title
Gawrieh et al. Saroglitazar, a PPAR‐α/γ agonist, for treatment of NAFLD: a randomized controlled double‐blind phase 2 trial
US10342770B2 (en) Treatment of NAFLD and NASH
EP3054940B1 (en) Compositions and methods for treating non-alcoholic steatohepatitis
US10441560B2 (en) Compositions and methods for treating non-alcoholic steatohepatitis
JP2023526418A (ja) 非アルコール性脂肪性肝炎（ｎａｓｈ）の処置
CN114555044B (zh) 酒精性肝炎的治疗
KR102205368B1 (ko) Fxr 작용제의 신규 요법
JP2023527153A (ja) 非アルコール性脂肪性肝炎（ｎａｓｈ）の処置
TW201440759A (zh) 治療脂肪肝疾病之方法
AU2018375298A1 (en) Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
WO2021237149A2 (en) Treatment of non-alcoholic steatohepatitis (nash)
HK40089720A (zh) 非酒精性脂肪性肝炎(nash)的治疗
HK40089967A (zh) 非酒精性脂肪性肝炎(nash)的治疗
WO2023210716A1 (ja) Ｃｂｐ／カテニン阻害剤の肝線維症治療レジメン
Mayatepek et al. Hepatic bile acid accretion correlates with cholestatic liver injury and therapeutic response in Cyp2c70 3 knockout mice with a humanized bile acid composition 4

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230126

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20230126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250527

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250530

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260303